Medicare’s New GLP-1 Weight Loss Program Is Complicated but Worth It

Medicare will begin offering certain weight-loss drugs for $50 per month starting July 1, 2026, but the program is temporary and structured outside standard prescription drug coverage, according to a NerdWallet analysis [1]. The initiative, called the Medicare GLP-1 Bridge short-term demonstration, is scheduled to run for 18 months and conclude on December 31, 2027 [1]. The program provides access to GLP-1 medications such as Wegovy, which shares an active ingredient with the diabetes drug Ozempic but is approved by the Food and Drug Administration for weight loss [1]. The $50 monthly copay represents a steep discount from Wegovy’s wholesale list price of $1,349.02 [1]. The Bridge program was originally designed as a precursor to a longer-term model called BALANCE, which would have shifted costs to Medicare plans with a government backstop [1]. The Centers for Medicare & Medicaid Services delayed BALANCE after the opt-in deadline for insurers passed in April, citing a need to collect data for a more effective implementation [1]. In response, CMS extended the Bridge program through the end of 2027 [1]. Beneficiaries must be enrolled in a Medicare Part D plan or a Medicare Advantage plan with prescription drug coverage to participate, but the $50 copay does not count toward a plan’s deductible or out-of-pocket maximum [1]. This means participants could face up to $600 annually in drug costs that fall outside their standard coverage [1]. Extra Help subsidies, which assist low-income beneficiaries with medication expenses, do not apply to GLP-1 drugs obtained through the Bridge program [1]. The financial stakes are substantial. Medicare spent over $19.3 billion on Ozempic and Mounjaro in 2024, placing them among the program’s highest-cost drugs even before covering them for weight loss [1]. The Department of Health and Human Services estimates roughly 14 million Medicare beneficiaries have obesity [1]. Extending coverage to even a fraction of that population could add billions in annual spending, a dynamic that mirrors pressures in global pharmaceutical markets where expanding access to costly drugs strains budgets [3]. CMS has not disclosed the projected cost of the Bridge program or detailed future plans for BALANCE [1]. UnitedHealthcare and Aetna, two large Medicare insurers, indicated they would use data from the Bridge program to inform potential future coverage models [1].